<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00230204</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-05-3868-AA-CTIL</org_study_id>
    <nct_id>NCT00230204</nct_id>
  </id_info>
  <brief_title>Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis</brief_title>
  <official_title>Antibodies Screening in Multiple Sclerosis as a Part of an International Survey in Autoimmune Diseases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to assess the prevalence of infectious disease
      seropositivity (toxoplasmosis, rubella, cytomegalovirus [CMV]), herpes simplex virus type 1
      (HSV-1) and herpes simplex virus type 2 (HSV-2), syphilis, Epstein-Barr virus and H. pylori
      in a group of patients presenting with specific autoimmune diseases (rheumatoid arthritis
      [RA], undifferentiated connective tissue disorder [UCTD], Sjogren, antiphospholipid syndrome
      - APS, vasculitides, systemic lupus erythematosus [SLE], polymyositis, Hashimoto, multiple
      sclerosis, primary biliary cirrhosis [PBC], etc.), using the BioPlex 2200 and complementary
      EIA kits as compared to matched controls (by age, sex and ethnicity).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this investigation is to assess the prevalence of infectious disease
      seropositivity (toxoplasmosis, rubella, cytomegalovirus [CMV]), herpes simplex virus type 1
      (HSV-1) and herpes simplex virus type 2 (HSV-2), syphilis, Epstein-Barr virus and H. pylori
      in a group of patients presenting with specific autoimmune diseases (RA, UCTD, Sjogren,
      antiphospholipid syndrome - APS, vasculitides, SLE, polymyositis, Hashimoto, multiple
      sclerosis, PBC, etc.), using the BioPlex 2200 and complementary EIA kits as compared to
      matched controls (by age, sex and ethnicity).

      We will assess in our Center 100 patients with multiple sclerosis for the antibody profile of
      different infectious agents. Comparative assessments will be performed with normal matched
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date>April 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine antibodies to infectious agents immunoglobulin G (IgG), IgM in patients with multiple sclerosis</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess correlation between antibody levels to various infectious agents with clinical disease variables</measure>
  </secondary_outcome>
  <enrollment>100</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Definite multiple sclerosis

        Exclusion Criteria:

          -  Intravenous immune globulin (IVIg) treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anat Achiron, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yehuda Shoenfeld</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anat Achiron, MD, PhD</last_name>
    <phone>972-3-5303811</phone>
    <email>achiron@post.tau.ac.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yehuda Shoenfeld, MD</last_name>
    <phone>972-3-5302652</phone>
    <email>shoenfel@post.tau.ac.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Multiple Sclerosis Center, Sheba Medical Center</name>
      <address>
        <city>Ramat-gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Levy</last_name>
      <phone>972-3-5303932</phone>
      <email>annlevy@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Anat Achiron, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2005</study_first_submitted>
  <study_first_submitted_qc>September 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2005</study_first_posted>
  <last_update_submitted>February 15, 2006</last_update_submitted>
  <last_update_submitted_qc>February 15, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2006</last_update_posted>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Serum</keyword>
  <keyword>Infectious agents</keyword>
  <keyword>Immunoglobulin G</keyword>
  <keyword>Immunoglobulin M</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

